{"commentary":{"count":7,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":5,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"STELLAR-311","nct_id":"NCT06943755","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stellar-311-nct06943755. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"STELLAR-311","arms":[{"description":"Participants will receive everolimus oral tablets once daily.","label":"Everolimus","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive zanzalintinib oral tablets once daily.","label":"Zanzalintinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-06-30","type":"ESTIMATED"},"conditions":["Pancreatic Neuroendocrine Tumor (pNET)","Extra-Pancreatic Neuroendocrine Tumor (epNET)"],"enrollment":{"count":440,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Zanzalintinib","type":"DRUG"},{"name":"Everolimus","type":"DRUG"}],"last_update":"2026-09-29","lead_sponsor":"Exelixis","official_title":"A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2029-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to 48 months"}],"references":[{"citation":"Chan JA, Strosberg JR, Yoo C, Singh S, Huang H, Goel M, Scheffold C, Capdevila J. STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors. Future Oncol. 2026 Sep 28:1-8. doi: 10.1080/14796694.2026.2733790. Online ahead of print.","pmid":"42803451","type":"DERIVED"}],"start_date":{"date":"2025-07-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","url":"https://clinicaltrials.gov/study/NCT06943755"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stellar-311-nct06943755"}